These features are driven by key pathways such as PI3K/AKT/mTOR, hypoxia/HIF‐1, NF‐kB, and TGF‐β/Smad, collectively highlighting their pivotal role in GBM chemoradiotherapy resistance (Figure S6A–D, Supporting Information). This evidence concerns the gene TGFB1 and glioblastoma.